Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadaaki Yamada

Showing results (31-40 of 228) with videos related to

Pageof 23
Sort By:
Oncotarget|June 23, 2014
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cellsAzusa Tanimoto, Tadaaki Yamada, Shigeki Nanjo, et al.
Pain|February 9, 2018
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 studyLynn R Webster, Srinivas Nalamachu, Bart Morlion, et al.
Therapeutic Advances in Gastroenterology|August 11, 2021
Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxativesMartin E Hale, James E Wild, Tadaaki Yamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism-Mediated Osimertinib Resistance in <i>EGFR-</i>Mutant Lung CancerAzusa Tanimoto, Shinji Takeuchi, Sachiko Arai, et al.
Translational Lung Cancer Research|October 17, 2022
Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancerYurie Seto, Yoshiko Kaneko, Takako Mouri, et al.
Therapeutic Advances in Medical Oncology|June 16, 2020
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)Tadaaki Yamada, Junji Uchino, Yusuke Chihara, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|November 30, 2004
[Severe asthma complicated with large mucoid impaction: successful removal with balloon catheter]Kazuhiro Nagata, Yoshinobu Iwasaki, Tadaaki Yamada, et al.
Translational Lung Cancer Research|September 27, 2019
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)Masahiro Iwasaku, Junji Uchino, Tadaaki Yamada, et al.
Respiratory Medicine|October 3, 2006
Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injuryKazuhiro Nagata, Yoshinobu Iwasaki, Tadaaki Yamada, et al.
Journal of Clinical Medicine|May 10, 2020
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A ReviewKeisuke Onoi, Yusuke Chihara, Junji Uchino, et al.
Pageof 23

Showing results (31-40 of 228) with videos related to

Sort By:
Pageof 23
Oncotarget|June 23, 2014
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cellsAzusa Tanimoto, Tadaaki Yamada, Shigeki Nanjo, et al.
Pain|February 9, 2018
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 studyLynn R Webster, Srinivas Nalamachu, Bart Morlion, et al.
Therapeutic Advances in Gastroenterology|August 11, 2021
Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxativesMartin E Hale, James E Wild, Tadaaki Yamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2016
Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism-Mediated Osimertinib Resistance in <i>EGFR-</i>Mutant Lung CancerAzusa Tanimoto, Shinji Takeuchi, Sachiko Arai, et al.
Translational Lung Cancer Research|October 17, 2022
Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancerYurie Seto, Yoshiko Kaneko, Takako Mouri, et al.
Therapeutic Advances in Medical Oncology|June 16, 2020
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)Tadaaki Yamada, Junji Uchino, Yusuke Chihara, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|November 30, 2004
[Severe asthma complicated with large mucoid impaction: successful removal with balloon catheter]Kazuhiro Nagata, Yoshinobu Iwasaki, Tadaaki Yamada, et al.
Translational Lung Cancer Research|September 27, 2019
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)Masahiro Iwasaku, Junji Uchino, Tadaaki Yamada, et al.
Respiratory Medicine|October 3, 2006
Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injuryKazuhiro Nagata, Yoshinobu Iwasaki, Tadaaki Yamada, et al.
Journal of Clinical Medicine|May 10, 2020
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A ReviewKeisuke Onoi, Yusuke Chihara, Junji Uchino, et al.
Pageof 23